RxDoctor Payments Data

Zhaohui Arter, MD

Hematology & Oncology · Orange, CANPI 1184116451

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,837 of the $18,562 with a category attached, or 63.8%. It is spread thinly across 16 manufacturers, the largest accounting for just 21.9%.

$18,562in general payments, 2019–2025

Across 38 payments — averaging $488.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$4K
  • Taiho Oncology, Inc.$3K
  • Rigel Pharmaceuticals, Inc.$3K
  • Catalyst Pharmaceuticals, Inc.$2K
  • Johnson & Johnson$2K
  • EMD Serono, Inc.$2K
  • plus $3K from 10 others
$198,489in research payments, 2019–2025

Across 9 payments — averaging $22,054 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Janssen Research & Development, LLC$137K
  • Genentech, Inc.$61K

What the payments were for

  • Consulting fees$11,83764%
  • Speaking & faculty fees$4,15522%
  • Travel & lodging$3942%
  • Food & beverage$2,07611%
  • Education$1001%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,562 in reported general payments places this provider in the 75th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024
$4,858
Medicare patients
14
Services billed
42

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Orange

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →